AUROPHARMA - Technical Analysis with Chart Patterns & Indicators
← Back to ListKey Parameters
⭐ Technical Rating: 3.0
✅ Positive
The stock demonstrates consistent quarterly profit growth, reaching 692 Cr. in the latest quarter compared to 595 Cr. previously. Furthermore, a recent licensing agreement with Merck for supplying a generic HIV drug indicates potential future revenue streams and expansion into new markets.
⚠️ Limitation
Despite positive earnings, the high P/E ratio of 37.8 suggests overvaluation relative to its peers in the industry. The significant volatility between the current price and the low of 1016 underscores inherent risk.
📉 Company Negative News
The upcoming AGM scheduled via VC might signal a lack of investor engagement or potentially highlight operational challenges, though no specific concerns were outlined.
📈 Company Positive News
The Merck licensing agreement is projected to generate revenue across 129 countries, expanding Aurobindo Pharma’s global reach and contributing to its growth trajectory.
🏭 Industry
The pharmaceutical sector continues to experience robust growth driven by aging populations, increasing healthcare expenditure, and the rising demand for generic drugs globally. Competition within this sector remains intense but also offers opportunities through innovation and strategic partnerships as seen in Aurobindo's recent agreement.
🧾 Conclusion
Based on the chart patterns, the stock is currently trading near its resistance level at 1,637 ₹. A potential entry zone could be established between 1,560 ₹ (support) and 1,590 ₹ (resistance). Exit zones would target a pullback to 1,520 ₹ or a breakout above 1,610 ₹. Overall, the stock appears to be trending upwards with moderate momentum, but investors should exercise caution due to its elevated valuation.